Q-omics provides the consensus-scored KRTAP17-1 profile across patient tissues and cancer cell-line models. KRTAP17-1 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, KRTAP17-1 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, KRTAP17-1 RNA expression shows 6,075 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, KIRC, and TGCT as cancer lineages where KRTAP17-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTAP17-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTAP17-1 survival associations across molecular data types. KRTAP17-1 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTAP17-1 RNA expression–survival associations across cancer types. High KRTAP17-1 expression shows unfavorable associations in LUAD, SKCM and GBM, but favorable associations in SCLC, OV and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for KRTAP17-1 RNA expression.
This table summarizes KRTAP17-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KRTAP17-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTAP17-1 shows lower tumor expression in KIRC and KICH and higher tumor expression in BRCA and LUSC. The KIRC box plot shows higher KRTAP17-1 RNA expression in normal versus tumor tissue (log2 FC = −0.260, t-test p < 0.001).
This table shows molecular features associated with KRTAP17-1 in patient tissues and cancer cell lines. In patient samples, KRTAP17-1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KRTAP17-1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
